Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Varenicline ups risk of cardiovascular events

28 Dec 2017
Adverse psychological effects caused by beta blockers add on to the depression experienced by many following cardiac surgery.

Varenicline, while effective for smoking cessation, appears to significantly elevate the risk of cardiovascular hospitalization and emergency department visits, particularly for new users, a recent study shows.

The research team examined the incidences of cardiovascular and neuropsychiatric hospitalizations in 56,851 new users of varenicline. Within 1 year before to 1 year after the receipt of the drug, they found a total of 6,317 cardiovascular and 10,041 neuropsychiatric events.

The incidence of cardiovascular events was significantly higher during the 12 weeks following varenicline initiation (risk interval) than during all other observation periods (control interval; relative incidence [RI], 1.34; 95 percent CI, 1.25–1.44; p<0.001). This trend remained significant even when the risk interval was changed to 4 weeks (RI, 1.30; 1.15–1.46; p<0.001), 8 weeks (RI, 1.42; 1.31–1.55; p<0.001), and 16 weeks (RI, 1.30; 1.22–1.39; p<0.001) following varenicline initiation.

Analysis by patient subgroup did not significantly change the observed association, with both <65-year (RI, 1.22; 1.10–1.34; p<0.001) and ≥65-year (RI, 1.53; 1.38–1.70; p<0.001) age groups showing significantly higher cardiovascular event incidence during the risk interval. Males and females also had similarly elevated incidences of cardiovascular events.

On the other hand, the incidence of neuropsychiatric events was also significantly elevated when the risk interval was set at 12 weeks (RI, 1.06; 1.00–1.13; p=0.042) or 16 weeks (RI, 1.06; 1.01–1.12; p=0.025) following varenicline initiation. In contrast, the incidence was not significantly higher 4 weeks and 8 weeks after initiation. Subgroup analysis also attenuated the association, with only individuals aged ≥65 years showing elevated incidence of neuropsychiatric events (RI, 1.44; 1.15‒1.80; p=0.002).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]